We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. After previously discontinuing infliximab, 35% of ...
Hidradenitis suppurativa (HS) is a difficult-to-treat skin condition that has responded to infliximab, although payer support in this setting is often lacking. Investigators have reported equivalent ...
BERLIN — Ulcerative colitis (UC) patients who fail on first-line therapy appear to have better outcomes with vedolizumab (Entyvio) than with infliximab, suggests EFFICACI, the first trial directly ...
The life of many individuals with inflammatory diseases such as rheumatoid arthritis has been dramatically improved by treatment with drugs that target the protein TNF, so called anti-TNF therapies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback